DOI 10.1016/j.jneuroim.2025.578835
Personalized Ofatumumab therapy for autoimmune encephalitis: A case series of four patients.
Аннотация
OBJECTIVE
Autoimmune encephalitis (AE), a prevalent neuroimmunological disorder, is primarily managed with immunotherapy. However, a subset of patients exhibits suboptimal responses to first-line treatments, and second-line options remain limited. This study investigates the efficacy and safety of a personalized ofatumumab (OFA) regimen guided by monitoring CD27 + CD19+ memory B cells in refractory AE.
METHODS
We report three cases of anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis and one case of antibody-negative AE (NA-AE) refractory to corticosteroids and intravenous immunoglobulin (IVIG). OFA was initiated at 20 mg subcutaneously on days 0 and 7, with subsequent doses administered when peripheral blood CD27 + CD19+ memory B cells exceeded 0.05 % of peripheral blood mononuclear cells (PBMCs).
RESULTS
After a median follow-up of 10 months (range: 6-12 months), all patients demonstrated clinical improvement, with significant reductions in modified Rankin Scale (mRS) and Clinical Assessment Scale in Autoimmune Encephalitis (CASE) scores. One patient experienced relapse post-SARS-CoV-2 infection, while the remainder remained recurrence-free without drug-related adverse events.
INTERPRETATION: CD27 + CD19+ memory B cell-guided OFA therapy may offer a novel strategy for refractory AE.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.